Pineal-opioid system interactions in the control of immunoinflammatory responses.
Several studies have demonstrated involvement of the pineal gland in the regulation of neuropeptide secretion and activity. In particular, the existence of links between the pineal gland and the brain opioid system has been documented. Both opioid peptides and melatonin (MLT), the most investigated pineal hormone, play an important role in neuromodulation of the immunity. Moreover, the immune effects of MLT are mediated by endogenous opioid peptides, which may be produced by both the endocrine system and the immune cells. In addition, the immune dysfunctions that characterize some human diseases, such as cancer, depend not only on the immune system per se, but also at least in part, on altered secretion of immunomodulating neurohormones, including MLT and opioid peptides. Therefore, the exogenous administration of neurohormones could potentially improve the immune status in humans. The present study evaluates the effects of MLT on changes in the number of T lymphocytes, natural killer cells, and eosinophils induced by exogenous administration of interleukin-2 (IL-2). Macrophage activity was also evaluated by determining serum levels of its specific marker, neopterin. The study was performed in 90 patients with advanced solid neoplasms, who received IL-2 at a dose of 3 million IU/day subcutaneously for 6 days a week for 4 weeks plus MLT at a daily dose of 40 mg. Both drugs were given in the evening. The results were compared to those in 40 cancer patients treated with IL-2 alone. The mean increase in T lymphocytes, natural killer cells, and eosinophils was significantly higher in patients treated with IL-2 plus MLT than in those who received IL-2 alone.(ABSTRACT TRUNCATED AT 250 WORDS)
Lissoni
P
P
Division of Radiation Oncology, San Gerardo Hospital, Monza, Milan, Italy.
Barni
S
S
Tancini
G
G
Fossati
V
V
Frigerio
F
F
D000328:Adult; D000368:Aged; D004804:Eosinophils; D005260:Female; D006801:Humans; D007167:Immunotherapy; D007249:Inflammation / Q000276:immunology*; D007376:Interleukin-2 / Q000627:therapeutic use; D007694:Killer Cells, Natural; D007958:Leukocyte Count; D018655:Lymphocyte Count; D008297:Male; D008550:Melatonin / Q000494:pharmacology* / Q000627:therapeutic use; D008875:Middle Aged; D009369:Neoplasms / Q000276:immunology / Q000503:physiopathology / Q000628:therapy; D018847:Opioid Peptides / Q000502:physiology*; D010870:Pineal Gland / Q000502:physiology*; D013601:T-Lymphocytes
D007376:Interleukin-2; D018847:Opioid Peptides; D008550:Melatonin